Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Rain Oncology Inc (RAIN)

Rain Oncology Inc (RAIN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,015
  • Shares Outstanding, K 36,376
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,720 K
  • 60-Month Beta 0.27
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.65
Trade RAIN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.06
  • Most Recent Earnings $-0.19 on 11/09/23
  • Latest Earnings Date 03/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.29
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.44
  • Prior Year -0.70
  • Growth Rate Est. (year over year) +58.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1850 +2.11%
on 01/02/24
1.2700 -4.72%
on 01/25/24
unch (unch)
since 12/22/23
3-Month
0.9900 +22.22%
on 11/29/23
1.2700 -4.72%
on 01/25/24
+0.1500 (+14.15%)
since 10/25/23
52-Week
0.8200 +47.56%
on 10/03/23
11.3200 -89.31%
on 02/13/23
-8.3000 (-87.28%)
since 01/25/23

Most Recent Stories

More News
ROSEN, A TOP RANKED LAW FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20,...

RAIN : 1.2100 (-1.63%)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023

/PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has...

RAIN : 1.2100 (-1.63%)
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

RAIN : 1.2100 (-1.63%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit....

RAIN : 1.2100 (-1.63%)
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit

/PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action...

RAIN : 1.2100 (-1.63%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are...

RAIN : 1.2100 (-1.63%)
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors with Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20,...

RAIN : 1.2100 (-1.63%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit....

RAIN : 1.2100 (-1.63%)
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action...

RAIN : 1.2100 (-1.63%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are...

RAIN : 1.2100 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc.,...

See More

Key Turning Points

3rd Resistance Point 1.3100
2nd Resistance Point 1.2900
1st Resistance Point 1.2500
Last Price 1.2100
1st Support Level 1.1900
2nd Support Level 1.1700
3rd Support Level 1.1300

See More

52-Week High 11.3200
Fibonacci 61.8% 7.3090
Fibonacci 50% 6.0700
Fibonacci 38.2% 4.8310
Last Price 1.2100
52-Week Low 0.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar